Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE versus LIDOCAINE HYDROCHLORIDE 0 4 AND DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE versus LIDOCAINE HYDROCHLORIDE 0 4 AND DEXTROSE 5 IN PLASTIC CONTAINER.
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE vs LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine blocks voltage-gated sodium channels on neuronal membranes, inhibiting the propagation of action potentials and resulting in local anesthesia.
Lidocaine is a amide-type local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses. Dextrose provides calories and does not have pharmacological activity.
0.25-0.5% solution, up to 2 mg/kg (max 150 mg) per dose via infiltration, peripheral nerve block, or epidural; may repeat every 3-6 hours as needed. For epidural: 0.5% solution, 15-20 mL for surgical anesthesia.
Intravenous administration: 1-1.5 mg/kg bolus, followed by 1-4 mg/min continuous infusion for ventricular arrhythmias. Maximum total dose: 3 mg/kg bolus; infusion for up to 24 hours. Note: 0.4% concentration = 4 mg/mL, 5% dextrose as diluent.
None Documented
None Documented
Terminal elimination half-life is 2.7 hours (range 1.5-5.5 hours). Prolonged up to 8-10 hours in neonates and 24-48 hours in severe hepatic impairment.
Terminal elimination half-life: 1.5–2 hours after a single dose in healthy adults. In patients with hepatic impairment, heart failure, or prolonged infusion, half-life can increase to >3 hours due to reduced clearance. Neonates: 3–6.3 hours.
Renal excretion accounts for approximately 95% of the dose, with about 50% excreted unchanged. The remainder is primarily hepatic metabolism followed by renal elimination of metabolites. Biliary/fecal excretion is minimal (<5%).
Renal: Approximately 90% of lidocaine is metabolized in the liver, and less than 10% is excreted unchanged in urine. The major metabolites (monoethylglycinexylidide and glycinexylidide) are excreted renally. Biliary/fecal excretion is minimal (<1%).
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)